spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

ACM Global Central Lab Expands to New Facility

US Specimen Processing Department moves to cater for growth in clinical trials

ACM Global Central Laboratory, the global central lab that continually defines the customer-service standard with its flexible approach, today announced the specimen processing department at its US site, located in Rochester, NY, has completed a successful move into a new 7,200 square feet facility. The specimen processing department, responsible for opening packages containing specimens shipped to ACM for testing, sample Quality Control and specimen accessioning, has expanded into space next door to the main site to allow for the increase in workload and capacity.

The move to the new facility was prompted by the very strong growth in the demand for ACM’s clinical trials support services. The specimen processing department outgrew the space available in ACM’s headquarters. There are a total of 18 workstations available for specimen processing in the new space. Eleven new workstations were set up during construction and the final seven workstations were moved from 160 Elmgrove Park to the new building on January 14, 2011. The new facility can also hold over 20 freezers, including a liquid nitrogen tank available for specimen storage.

Renay Moore heads the department as Director of Clinical Trials Support Operations. Renay has been with ACM for over six years and was recently promoted from her role as a Senior Project Manager.

“We are excited to announce the expansion of the specimen processing department here in Rochester”, said Renay Moore. “This project started back in July 2010 and it’s thanks to the hardwork and support of our contractors and employees that the re-location has been carried out in such a timely manner.”

About ACM Global Central Laboratory
ACM Global Central Laboratory offers a flexible approach and a focus on precision to keep clinical research studies on schedule. ACM’s operations extend to more than 60 countries with all tests conducted and managed from central lab facilities with seamless data management providing a single database. The organization performs 13 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting. For more information, visit www.acmgloballab.com.

 
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>


White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement